Adjuvants: Classification, Modus Operandi, and Licensing
about
Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4.Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice.Antibody Engineering for Pursuing a Healthier FutureTargeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses.Old and new adjuvants.Total Leishmania antigens with Poly(I:C) induce Th1 protective response.Process signatures in glatiramer acetate synthesis: structural and functional relationships.Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins.Vaccine adjuvants: smart components to boost the immune system.Strategies for Generating Diverse Antibody Repertoires Using Transgenic Animals Expressing Human Antibodies.Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice.Systematic Overview of Solid Particles and Their Host Responses.Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4 T Cell-Independent CD8 T-Cell Response Against Unconjugated Protein AntigenGenetic Engineering of Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype
P2860
Q33785689-23256BBC-FE2E-4959-AA94-149CFA1FF107Q37539243-9C79CFAA-6D30-4B00-9378-C3896E52C3DFQ38731632-B1CE48AB-2154-416A-B0BB-87AF8A26D732Q39432584-FF42FACD-771D-40D7-91D3-08C0CA6916FAQ39451745-36E28F75-331C-4260-8949-749CB60EF923Q40049613-856BBB86-9A6E-432E-ABDA-37863028DD8DQ42362266-3DE201B9-19FC-40F8-AF3D-EE0BC8CF2B7FQ47144502-C706706D-60AC-4AC7-BC20-871F55208464Q50063256-52FC744D-B3DA-459B-A006-47CC453D6832Q52643675-3DA98B92-B9E0-4EF4-8DF4-A9BFC177759CQ54230568-5DAE3E5E-0517-42BD-AD11-FABF59F063B3Q55216329-7B712C0E-349E-418F-AD37-6D5DA405CD15Q58575827-17229E0E-FF6C-4CFE-B32E-3D75F8ADCB4DQ58764447-A35EC90D-4EAD-4CA5-A699-B29A2AD8390B
P2860
Adjuvants: Classification, Modus Operandi, and Licensing
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Adjuvants: Classification, Modus Operandi, and Licensing
@ast
Adjuvants: Classification, Modus Operandi, and Licensing
@en
Adjuvants: Classification, Modus Operandi, and Licensing
@nl
type
label
Adjuvants: Classification, Modus Operandi, and Licensing
@ast
Adjuvants: Classification, Modus Operandi, and Licensing
@en
Adjuvants: Classification, Modus Operandi, and Licensing
@nl
prefLabel
Adjuvants: Classification, Modus Operandi, and Licensing
@ast
Adjuvants: Classification, Modus Operandi, and Licensing
@en
Adjuvants: Classification, Modus Operandi, and Licensing
@nl
P2860
P50
P3181
P356
P1476
Adjuvants: Classification, Modus Operandi, and Licensing
@en
P2093
Juliana de Souza Apostólico
P2860
P304
P3181
P356
10.1155/2016/1459394
P407
P577
2016-05-04T00:00:00Z